The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Febseltiq infigratinib Orphan | Helsinn Birex Pharmaceuticals Ltd | Cholangiocarcinoma | 🇪🇺 EU | Order → |
| Feraheme ferumoxytol | Covis Pharma Europe B.V. | Anemia, Iron-Deficiency | 🇪🇺 EU | Order → |
| Fluad Paediatric | Novartis Vaccines and Diagnostics S.r.l. | 🇪🇺 EU | Order → | |
| Flynpovi eflornithine;sulindac Orphan | Cancer Prevention Pharma (Ireland) Limited | Adenomatous Polyposis Coli | 🇪🇺 EU | Order → |
| Folcepri Etarfolatide Orphan | Endocyte Europe, B.V. | Ovarian Neoplasms; Radionuclide Imaging | 🇪🇺 EU | Order → |
| Folotyn pralatrexate Orphan | Allos Therapeutics Ltd | Lymphoma, T-Cell | 🇪🇺 EU 2012-04-19 | Order → |
| Fondaparinux sodium Evumed fondaparinux sodium Generic | Evumed Limited | Venous Thrombosis; Pulmonary Embolism; Myocardial Infarction; Angina, Unstable | 🇪🇺 EU 2026-11-12 | Order → |
| Foundayo Orforglipron | Eli Lilly Nederland B.V. | Obesity; Overweight; Diabetes Mellitus | 🇪🇺 EU 2026-10-15 | Order → |
| Fovlussea ranibizumab Biosimilar | Accord Healthcare S.L.U. | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Choroidal Neovascularization | 🇪🇺 EU 2026-10-15 | Order → |
| Frehemgo denecimig | Novo Nordisk A/S | Hemophilia A | 🇪🇺 EU 2026-09-17 | Order → |
| Fulphila pegfilgrastim Biosimilar | Mylan S.A.S | 🇪🇺 EU | Order → | |
| Fyzoclad adalimumab | Pfizer Europe MA EEIG | Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid; Psoriasis; Arthritis, Psoriatic; Spondylitis, Ankylosing; Uveitis | 🇪🇺 EU | Order → |
| Gamifant emapalumab OrphanPRIME | Swedish Orphan Biovitrum AB (publ) | Immune System Diseases | 🇪🇺 EU 2020-09-17 | Order → |
| Garenoxacin mesylate garenoxacin mesylate | Schering-Plough Europe | Surgical Wound Infection; Sinusitis; Skin Diseases, Infectious; Pneumonia; Soft Tissue Infections; Bronchitis, Chronic | 🇪🇺 EU | Order → |
| Garsun artesunate Orphan | B And O Pharm | Malaria | 🇪🇺 EU | Order → |
| Garzulys insulin aspart Biosimilar | Sciencepharma Sp. z o.o | Diabetes Mellitus | 🇪🇺 EU 2026-11-12 | Order → |
| Gastromotal 1-13C-caprylic acid | INFAI, Institut für biomedizinische Analytik NMR-Imaging GmbH | Gastric Emptying; Breath Tests | 🇪🇺 EU | Order → |
| Gefzuris gefapixant | Merck Sharp & Dohme B.V. | Cough | 🇪🇺 EU | Order → |
| GeGant germanium (68Ge) chloride;gallium (68Ga) chloride | ITM Medical Isotopes GmbH | Radionuclide Imaging | 🇪🇺 EU | Order → |
| Gemesis becaplermin | BioMimetic Therapeutics Ltd | Guided Tissue Regeneration, Periodontal | 🇪🇺 EU 2009-11-19 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.